Tesamorelin results:
before and after, week by week.

The first month of tesamorelin therapy produces measurable biochemical changes but minimal visible body composition change. This is normal and expected — visceral fat mobilization is a slow process that unfolds over weeks, not days, and early results are dominated by the upstream signaling changes that precede physical transformation.

Week 1. IGF-1 levels begin rising within 48–72 hours of the first dose and typically reach a new steady state within 5–7 days. Most patients at standard 2 mg dosing see IGF-1 rise from baseline into the upper half of the age-adjusted physiologic range. Sleep quality often improves within the first week — users commonly report deeper sleep and fewer nocturnal awakenings in the first several days of therapy. Mild injection site reactions may appear — redness, itching, minor bruising. These are typically the most prominent side effect in the first week and resolve with site rotation.

Weeks 2–3. Peripheral edema and mild fluid retention may appear, particularly in the hands and feet. This is a characteristic early effect of elevated GH/IGF-1 and usually peaks around weeks 2–3 before gradually resolving as the body adapts. Mild arthralgia — joint aching, particularly in the hands and wrists — can emerge in this window. Scale weight may tick up 1–2 pounds from fluid retention without reflecting fat gain. Subjective energy and recovery from exercise often improve.

Week 4. By the end of the first month, biochemical changes are established and the early side effect wave is usually resolving. Visceral fat has begun to mobilize but is not yet substantially reduced. Waist circumference may have decreased by 0.5–1 cm on average, imperceptibly to the patient. This is the month where patience matters — the cumulative tesamorelin before-and-after transformation hasn't begun visibly but the metabolic groundwork is laid.

The second and third months of tesamorelin therapy are when visible body composition changes typically become apparent. Visceral fat is actively mobilizing, waist circumference starts to decrease meaningfully, and the early biochemical changes begin translating into physical transformation.

Weeks 4–8. Waist circumference reduction becomes noticeable — typically 1–2 cm over this window, though individual variation is substantial. Abdominal profile begins flattening, particularly in the upper abdomen where visceral fat accumulates most. Clothing fit changes are often the first subjective marker: pants fit more loosely at the waist while remaining unchanged at the hips and thighs, consistent with selective VAT loss. Scale weight remains relatively stable or trends slightly down (1–3 pounds net) — the fat loss is partially offset by continued fluid retention and modest lean mass increase.

Weeks 8–12. By 3 months of tesamorelin therapy, the mean visceral fat reduction on imaging is approximately 8–10% — about half of the 26-week endpoint. Waist circumference is typically 1.5–3 cm below baseline. Abdominal profile changes are visible in photos and to close observers. Subcutaneous fat is largely unchanged, which reinforces the body recomposition pattern rather than general fat loss. Lean body mass has increased by roughly 0.5–1 kg, reflecting modest anabolic effects of elevated IGF-1. Side effects have usually diminished — arthralgia and edema are less common at 3 months than at week 2.

The 26-week endpoint is where the Phase III clinical trials defined the primary efficacy outcome and where most of the tesamorelin before-and-after transformation has been achieved. Patients at this point typically show visible abdominal changes, measurable VAT reduction on imaging, and stable biochemical markers.

Visceral fat at 26 weeks. Mean VAT reduction across the Phase III trials was 15.2% at the 26-week endpoint. Individual response ranges from roughly 5% to over 30%, with some of this variability attributable to baseline VAT mass (patients with more visceral fat at baseline lose a higher absolute amount, though the percentage reduction is similar). Subcutaneous fat change at 26 weeks averages only 1–2%, maintaining the selective VAT effect.

Waist circumference at 26 weeks. Mean waist reduction in the trials was 2.6 cm. Clinically meaningful changes in the belt-notch sense — 3–4 cm or more — are common in patients who had significant visceral adiposity at baseline.

Lean body mass at 26 weeks. Mean increase of 1.3 kg across the Phase III trials. Modest but meaningful, particularly when combined with the visceral fat reduction.

Body weight at 26 weeks. Mean weight change is typically in the range of -2 to +1 kg — often net-neutral. Because tesamorelin swaps visceral fat for lean mass, scale weight is a poor indicator of response. Waist circumference, body composition measurement, or abdominal photography capture the real transformation.

IGF-1 and biochemical markers. IGF-1 remains elevated in the upper physiologic range. Triglycerides typically trend down 10–15%. HDL cholesterol often trends slightly upward. Fasting glucose has either stabilized or returned near baseline after any early rise.

Subjective measures. Sleep quality, recovery, and energy are generally improved relative to baseline. Skin quality (collagen density, elasticity) may show modest improvement but is usually subtle at 6 months and more pronounced at 12+ months of continued therapy.

Extending tesamorelin therapy beyond the 26-week primary endpoint produces additional but diminishing returns. The dose-response curve flattens, with roughly a 3-percentage-point additional VAT reduction over the second 26 weeks compared to the first.

Visceral fat at 52 weeks. Mean VAT reduction of 18%, compared to 15% at 26 weeks. The additional 3% comes primarily in the first 10 weeks of the extension period; patients who continue beyond 40 weeks see very little additional VAT loss.

Liver fat at 12 months. This is where the Stanley et al. JAMA 2014 study becomes relevant — in HIV patients with NAFLD, 12 months of tesamorelin produced a mean hepatic fat fraction reduction of 32% on MRI. This is a larger relative effect than on VAT because liver fat is particularly responsive to GH-mediated lipolysis. Patients with fatty liver at baseline (whether HIV-related or otherwise) often see the most dramatic tesamorelin before-and-after response in this ectopic-fat compartment.

Lean body mass at 52 weeks. Roughly 1.5–2 kg gained above baseline — slightly more than the 26-week endpoint. The lean mass benefit plateaus over time but is preserved through continued therapy rather than reversing.

Discontinuation and rebound. Stopping tesamorelin after 52 weeks of therapy produces gradual VAT rebound over 3–6 months as the GH axis returns to baseline. Patients who want to maintain results long-term either continue therapy indefinitely, cycle with 26 weeks on / 26 weeks off, or transition to a lower-intensity maintenance protocol — sometimes including stacks with ipamorelin or downshift to sermorelin for general GH support.

Because tesamorelin produces body recomposition rather than scale-weight loss, standard weight tracking is a poor way to measure tesamorelin results. Patients who rely on the bathroom scale alone are often disappointed by week 8 and may discontinue before the cumulative tesamorelin before-and-after effect becomes visible. Better tracking methods capture what tesamorelin actually changes.

Waist circumference. Measure at the umbilicus (belly button) with a tape measure, exhaling gently without sucking in. Same time of day (morning is ideal), same conditions, weekly or biweekly. A 2–4 cm reduction over 26 weeks is typical and meaningful.

Abdominal photography. Front and side photos in the same lighting and pose at baseline, 4 weeks, 12 weeks, and 26 weeks. Photos capture the abdominal profile change that tesamorelin produces more clearly than scale weight. This is especially useful because visceral fat reduction changes the shape of the abdomen (flatter, less protruding) even when subcutaneous fat is unchanged.

Body composition scans. DEXA scans before starting and at 26 weeks provide direct measurement of visceral fat, subcutaneous fat, and lean mass. This is the gold standard for tracking tesamorelin results but requires access to a DEXA machine. InBody and similar bioimpedance scales are less accurate but can show directional trends.

IGF-1 blood tests. Baseline IGF-1, 4-week follow-up, and 12-week follow-up labs document the biochemical response. Useful both for confirming the protocol is working and for ensuring IGF-1 stays within the physiologic range rather than rising supraphysiologically.

Subjective markers. Sleep quality, recovery from training, energy levels, clothing fit. These are captured in weekly journaling. Because tesamorelin's effects include non-body-composition benefits, subjective tracking captures response that instruments miss.